Safety and Efficacy of Hepatitis a Vaccination in Liver Transplantation Recipients1, 2

Abstract

HAV vaccination is safe in OLT recipient. Efficacy of HAV vaccination in OLT recipients, as measured by a commercially available enzyme immunoassay, is low and alternative strategies should be developed to improve response rate.

Susceptibility to Hepatitis A in Patients With Chronic Liver Disease Due to Hepatitis C Virus Infection: Missed Opportunities for Vaccination *

“…43,44 Although the HAV vaccine is also safe in patients with decompensated disease and in liver transplant recipients, the immunogenicity of the vaccine is substantially lower than in those with compensated liver disease. 42,45,46 Therefore, early vaccination against HAV is important in patients with chronic liver disease.…”

Prevenção das hepatites virais através de imunização

“…4,6 Recently there was an important change in the seroconversion rates [28][29][30][31] (Table 2). The response of patients with decompensated chronic hepatic disease is known to be lower, with lower antibody levels and lower seroconversion rates, when compared to those with compensated disease.…”

Loss of hepatitis A virus (HAV) antibodies after peripheral stem cell transplantation (PSCT)

“…Although there are no studies regarding immunogenicity of this vaccine among PSCT recipients, it has been shown to be safe and immunogenic in other immunocompromised hosts. [23][24][25][26][27] In conclusion, 14% of nonvaccinated anti-HAV seropositive patients can lose these antibodies 1 year following PSCT. We recommend immunizing these patients.…”